Timothy P. Walbert

Chairman, President & Chief Executive Officer at Horizon Therapeutics Plc

Timothy P. Walbert

Timothy P. Walbert

Chairman, President & Chief Executive Officer at Horizon Therapeutics Plc

Overview
Career Highlights

Viela Bio, Inc.
Horizon Therapeutics Plc
Horizon Therapeutics USA, Inc.

RelSci Relationships

4437

Number of Boards

25

Birthday

1968

Age

53

Relationships
RelSci Relationships are individuals Timothy P. Walbert likely has professional access to. A relationship does not necessarily indicate a personal connection.

Executive Vice President, Chief Medical Officer at Horizon Therapeutics Plc

Relationship likelihood: Strong

Director at Atterx BioTherapeutics

Relationship likelihood: Strong

Chief Financial Officer at BioQ Pharma, Inc.

Relationship likelihood: Strong

Venture Partner at Pappas Capital LLC

Relationship likelihood: Strong

Executive Vice President & Chief Financial Officer at Horizon Therapeutics Plc

Relationship likelihood: Strong

Chairman at Crealta Pharmaceuticals LLC

Relationship likelihood: Strong

Managing Director at Essex Woodlands Management, Inc.

Relationship likelihood: Strong

Director at Horizon Therapeutics USA, Inc.

Relationship likelihood: Strong

Co-Founder at Translate Bio, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Aurinia Pharmaceuticals, Inc.

Relationship likelihood: Strong

Paths to Timothy P. Walbert
Potential Connections via
Relationship Science
You
Timothy P. Walbert
Chairman, President & Chief Executive Officer at Horizon Therapeutics Plc
Education
BA in Business & Marketing

Founded in 1848, Muhlenberg is a highly selective, private, four-year liberal arts college. The College took its present name in 1867 from Henry Melchior Muhlenberg, patriarch of the Lutheran Church in the American Colonies. The College offers 40 majors in the humanities, fine arts, social sciences and natural sciences, in addition to strong pre-professional programs in such areas as pre-health, pre-law, pre-theology, business and education.

Memberships
Member
Current

CEO Action For Diversity & Inclusion is the CEO-driven business commitment to advance diversity and inclusion within the workplace. The company is headquartered in Chicago, IL.

Career History
President & Director
2021 - Current

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.

Chairman, President & Chief Executive Officer
2008 - Current

Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

President, Chief Executive Officer, Chairman
Current

Horizon Therapeutics USA, Inc. develops prescription drugs for mild to moderate pain relief arthritis. The company is headquartered in Northbrook, IL.

Boards & Committees
Member, Board of Directors
2007 - 2009

IDM Pharma, Inc. develops products for the destruction of cancer cells. Its products activate the immune system or prevent recurrence by triggering adaptive immune response. The company was founded in established on October 1987 and is headquartered in Cambridge, MA.

Transactions
Details Hidden

Horizon Therapeutics Plc issued USD Ordinary Shares

Details Hidden

Horizon Therapeutics, Inc. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Timothy P. Walbert. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Timothy P. Walbert's profile does not indicate a business or promotional relationship of any kind between RelSci and Timothy P. Walbert.